--------------------------------------------------------------------------------
--------------------------------------------------------------------------------


                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549



                                    Form 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): April 19, 1999




                         Commission file number 0-17714




                           BIOPOOL INTERNATIONAL, INC.
             (Exact name of Registrant as specified in its charter)




          Delaware                                         58-1729436
(State or other jurisdiction of                        (I.R.S. Employer
 incorporation or organization)                         Identification No.)




                               6025 Nicolle Street
                            Ventura, California 93003
                    (Address of principal executive offices)



                                 (805) 654-0643
               (Registrant's telephone number including area code)




--------------------------------------------------------------------------------
--------------------------------------------------------------------------------




<PAGE>




ITEM 5.   OTHER EVENTS

     Reference is made to the press release of  Registrant,  issued on April 19,
1999,  which contains  information  meeting the requirements of this Item 5, and
which is incorporated  herein by this reference.  A copy of the press release is
attached to this Form 8-K as Exhibit "A."









                                   SIGNATURES


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.





Date:  April 20, 1999                    BIOPOOL INTERNATIONAL, INC. 
       ---------------                   ---------------------------
                                         (Registrant)





                                         /s/  Michael D. Bick, Ph.D.
                                         ---------------------------
                                         Michael D. Bick, Ph.D.
                                         Chief Executive Officer and
                                         Chairman of the Board


                                        2

<PAGE>


                                    EXHIBIT A



CONTACTS:              Michael D. Bick, Ph.D.
                       Chairman and Chief Executive Officer

                       Carol Hill
                       Corporate Communications
                       (805) 654-0643



FOR IMMEDIATE RELEASE


              BIOPOOL INTERNATIONAL TO TRADE ON OTC BULLETIN BOARD

VENTURA, California (April 19, 1999)--Biopool  International,  Inc. (OTCBB:BIPL)
today  announced that effective this date its shares will no longer trade on the
Nasdaq's  SmallCap  Market because the bid price for its shares has fallen below
the $1.00 per share Nasdaq minimum listing maintenance requirement.
         The  Company's  stock  now  immediately  qualifies  to trade on the OTC
Bulletin Board under the symbol  "BIPL."  Michael D. Bick,  Ph.D.,  chairman and
chief  executive  officer of Biopool,  commented,  "The move to the OTC Bulletin
Board in no way reflects any adverse  financial  conditions  within the Company.
Indeed we meet and exceed all listing  requirements for Nasdaq other than the $1
minimum bid price."
         Founded in 1987,  Biopool  International  develops,  manufactures,  and
markets a full  range of test kits to assess  and  diagnose  disorders  of blood
coagulation,  thrombotic risk factors, fibrinolysis,  platelet function, and the
vascular system and specialty chemistry controls used to monitor and measure the
presence of drugs of abuse.  The  Company's  product line is sold to  hospitals,
clinical   laboratories,   commercial  reference   laboratories,   and  research
institutions on a worldwide basis by the Company's own sales representatives, as
well as  through  an  extensive  network  of  distributors.  To learn more about
Biopool, visit the Company's website at http://www.biopool.com.

NOTE: This press release  contains  forward-looking  statements  which are based
upon  current  expectations  that  involve a number  of risks and  uncertainties
including, but not limited to, technological innovations of competitors, changes
in health care regulations,  litigation  claims,  foreign currency  fluctuation,
product  acceptance  or  changes  in  government  regulation  of  the  Company's
products,  as well as other factors  discussed in the  Company's  last Report on
Form 10-K-SB under "Risk Factors."

                                      # # #

                                        3
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 5026}]
{"company-data": {"conformed-name": "BIOPOOL INTERNATIONAL INC", "cik": "0000830736", "assigned-sic": "2835", "irs-number": "581729436", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14257", "film-number": "99597842"}, "business-address": {"street1": "6025 NICOLLE ST SUITE A", "city": "VENTURA", "state": "CA", "zip": "93003", "phone": "8056540643"}, "mail-address": {"street1": "6025 NICOLLE STREET", "city": "VENTURA", "state": "CA", "zip": "93003"}, "former-company": {"former-conformed-name": "CYTRX BIOPOOL LTD", "date-changed": "19890716"}}
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    Form 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): April 19, 1999

                         Commission file number 0-17714

                           BIOPOOL INTERNATIONAL, INC.
             (Exact name of Registrant as specified in its charter)

          Delaware                                         58-1729436
(State or other jurisdiction of                        (I.R.S. Employer
 incorporation or organization)                         Identification No.)

                               6025 Nicolle Street
                            Ventura, California 93003
                    (Address of principal executive offices)

                                 (805) 654-0643
               (Registrant's telephone number including area code)

--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
ITEM 5.   OTHER EVENTS

     Reference is made to the press release of  Registrant,  issued on April 19,
1999,  which contains  information  meeting the requirements of this Item 5, and
which is incorporated  herein by this reference.  A copy of the press release is
attached to this Form 8-K as Exhibit "A."

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

Date:  April 20, 1999                    BIOPOOL INTERNATIONAL, INC. 
       ---------------                   ---------------------------
                                         (Registrant)

                                         /s/  Michael D. Bick, Ph.D.
                                         ---------------------------
                                         Michael D. Bick, Ph.D.
                                         Chief Executive Officer and
                                         Chairman of the Board

                                        2
EXHIBIT A

CONTACTS:              Michael D. Bick, Ph.D.
                       Chairman and Chief Executive Officer

                       Carol Hill
                       Corporate Communications
                       (805) 654-0643

FOR IMMEDIATE RELEASE

              BIOPOOL INTERNATIONAL TO TRADE ON OTC BULLETIN BOARD

VENTURA, California (April 19, 1999)--Biopool  International,  Inc. (OTCBB:BIPL)
today  announced that effective this date its shares will no longer trade on the
Nasdaq's  SmallCap  Market because the bid price for its shares has fallen below
the $1.00 per share Nasdaq minimum listing maintenance requirement.
         The  Company's  stock  now  immediately  qualifies  to trade on the OTC
Bulletin Board under the symbol  "BIPL."  Michael D. Bick,  Ph.D.,  chairman and
chief  executive  officer of Biopool,  commented,  "The move to the OTC Bulletin
Board in no way reflects any adverse  financial  conditions  within the Company.
Indeed we meet and exceed all listing  requirements for Nasdaq other than the $1
minimum bid price."
         Founded in 1987,  Biopool  International  develops,  manufactures,  and
markets a full  range of test kits to assess  and  diagnose  disorders  of blood
coagulation,  thrombotic risk factors, fibrinolysis,  platelet function, and the
vascular system and specialty chemistry controls used to monitor and measure the
presence of drugs of abuse.  The  Company's  product line is sold to  hospitals,
clinical   laboratories,   commercial  reference   laboratories,   and  research
institutions on a worldwide basis by the Company's own sales representatives, as
well as  through  an  extensive  network  of  distributors.  To learn more about
Biopool, visit the Company's website at http://www.biopool.com.

NOTE: This press release  contains  forward-looking  statements  which are based
upon  current  expectations  that  involve a number  of risks and  uncertainties
including, but not limited to, technological innovations of competitors, changes
in health care regulations,  litigation  claims,  foreign currency  fluctuation,
product  acceptance  or  changes  in  government  regulation  of  the  Company's
products,  as well as other factors  discussed in the  Company's  last Report on
Form 10-K-SB under "Risk Factors."

                                      # # #

                                        3